Company intelligence / Profile preview
Enhanced Genomics
Cambridge, Cambridgeshire, United Kingdom
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
Enhanced Genomics is a UK-based biotech advancing a preclinical pipeline using its proprietary 3D multi-omics technology and functional genomics to rapidly identify, validate, and prioritize novel drug targets for common and complex genetic diseases, especially those with large unmet medical needs like autoimmune conditions and inflammatory bowel disease. No publicly disclosed clinical-stage assets as of October 2025.
- Therapeutic areas
- GastroenterologyImmunologyInfectious Diseases
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
ALBORADA Drug Discovery Institute
Beyond the preview
Go deeper on Enhanced Genomics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enhanced Genomics.